1. Home
  2. Companies
  3. ACR
  4. Material Events

Acrux (ASX:ACR) — Material Events

ASX:ACR · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 9 articles Notable 5 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
9
FDA confirms Acrux Phase III path for female testosterone sprayHigh
FDA confirms Phase III pathway and potential three-year exclusivity for Acrux female testosterone spray
12 Oct 2026 ·Regulatory Update ·86
Acrux Accelerates Female Testosterone Development with $5M Revenue Surge and FDA Phase III ClarityMedium
Acrux reports strong revenue growth, FDA Phase III pathway for Female Testosterone, and $1.6M funding
31 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
Acrux Narrows FY26 Loss 90% as Female Testosterone Development Gains MomentumMedium
Acrux FY26 revenue up 46%, net loss narrows 90%, advances Female Testosterone MDTS development
26 Aug 2026 ·Annual Financial Report and Results Announcement ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.